is the Sclerostin Marker of Chronic Periodontitis

NCT03639636 | Completed DMC

• 1 other identifier: madhavisclerostin
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Reviewed literature suggests that sclerostin will inhibit the bone formation and ultimately leads to chronic periodontitis. Estimation of Sclerostin levels in the serum of periodontitis patients before and after intervention could explore the effectiveness of therapy and also give a more detailed insight into its diagnostic and prognostic potential as a biomarker of periodontal disease.

Conditions

Periodontitis

Keywords

periodontitis; sclerostin; periodontal surgery; scaling and root planing

Outcome Measures

Primary Outcomes (1)

• sclerostin level response to only scaling and root planing

  measuring serum sclerostin levels in pg/ml(Pico grams per milli liter),

  4 weeks

Secondary Outcomes (1)

• sclerostin level response to periodontal surgery

  6 weeks

Other Outcomes (1)

• periodontal parametors

  0-4-6 weeks

Study Arms (1)

interventional prospective study

OTHER

nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)

Other: non surgical and surgical periodontal therapy

Interventions

non surgical and surgical periodontal therapy OTHER

scaling and root planing periodontal flap surgery

interventional prospective study

Eligibility Criteria

• Age: 30 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• All the patients who are diagnosed as having generalized chronic periodontitis based on the American Academy of Periodontology (AAP) classification.
• Probing Pocket Depth (PPD)/ Clinical Attachment Loss(CAL) ≥ 5mm
• Patients indicated for periodontal surgery

You may not qualify if:

• Patients having any other systemic diseases
• Patients taking high-dose steroid therapy, radiation or immunosuppressive therapy and any other drug history.
• Pregnant and lactating woman.
• History of smoking within the past five years.
• Patients who had undergone periodontal therapy in the last six months.
• Intellectual disability

Sponsors & Collaborators

• Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre: lead

Study Sites (1)

Panineeya Institute of Dentalsciences and Research Center

Hyderabad, Telangana, 500060, India

Location

Related Publications (4)

• Liu M, Kurimoto P, Zhang J, Niu QT, Stolina M, Dechow PC, Feng JQ, Hesterman J, Silva MD, Ominsky MS, Richards WG, Ke H, Kostenuik PJ. Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss. J Dent Res. 2018 Aug;97(9):1031-1038. doi: 10.1177/0022034518766874. Epub 2018 Apr 4.

  PMID: 29617179 BACKGROUND

• Chen H, Xu X, Liu M, Zhang W, Ke HZ, Qin A, Tang T, Lu E. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. Bone. 2015 Jul;76:141-8. doi: 10.1016/j.bone.2015.04.002. Epub 2015 Apr 11.

  PMID: 25868799 BACKGROUND

• Taut AD, Jin Q, Chung JH, Galindo-Moreno P, Yi ES, Sugai JV, Ke HZ, Liu M, Giannobile WV. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013 Nov;28(11):2347-56. doi: 10.1002/jbmr.1984.

  PMID: 23712325 RESULT

• Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-kappaB Ligand in Periodontitis. J Periodontol. 2015 Dec;86(12):1396-404. doi: 10.1902/jop.2015.150270. Epub 2015 Sep 14.

  PMID: 26367496 RESULT

MeSH Terms

Conditions

Periodontitis; Sclerosteosis

Condition Hierarchy (Ancestors)

Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases

Study Officials

• Jammula surya prasanna, mds

  panineeya institute of dental sciences and research center

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.banda madhavi

Model Details: interventional prospective study

Study Record Dates

• First Submitted: August 10, 2018
• First Posted: August 21, 2018
• Study Start: June 1, 2017
• Primary Completion: December 20, 2017
• Study Completion: May 15, 2018
• Last Updated: August 21, 2018

Record last verified: 2018-08

Data Sharing

• IPD Sharing: Will not share

Locations

IN (1)